Xvivo Perfusion AB

XVIVO

Equity

ISIN SE0004840718 / Valor 19661174

NASDAQ Nordic Exchange Stockholm, Equities (2026-05-05)

SEK 268.80-1.90%

Xvivo Perfusion AB
UMushroom community rating:

3.00 1 votes No rating yet

NegativeNeutralPositive

About company

Xvivo Perfusion AB, headquartered in Gothenburg, Sweden, is a publicly traded company listed on Nasdaq with offices and research facilities across two continents. The company specializes in developing machine perfusion technologies designed to preserve and enhance the viability of organs such as kidneys, livers, and lungs for transplantation. In addition to its advanced perfusion systems, Xvivo offers solutions for the cold static storage of lungs and provides comprehensive organ recovery and perfusion services. These offerings aim to improve the success rates of organ transplants by extending the preservation window and maintaining organ function prior to transplantation.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-14.8%1Y

-12.2%3Y

-17.2%5Y

Performance

63.3%1Y

52.6%3Y

51.7%5Y

Volatility

921 M

Market cap (USD)

52,886

Daily traded volume (Shares)

491 / 472.5

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.00

1 votes

Performance:

3.00

Innovation:

5.00

Society:

4.00

Nature:

3.00

Andreas Kienast

Switzerland, 27 Mar 2025

Medizinaltechik. Für das Retten von Leben sind die Menschen bereit, viel zu investieren. Der Kurs hat eine attraktive Tiefe. Hauptsitz in einer politisch Stabilen Gegend.

EQUITIES OF THE SAME SECTOR

Alnylam Pharmaceuticals Inc